Australian consumer sentiment remained in the doldrums in February, a survey showed on Tuesday, failing to benefit from ...

The great majority of Significant Investor Visa holders are just very good business people with money to invest in Australia ...

Australian biopharmaceutical company CSL posted higher first-half profits as growth in its main blood-plasma business helped offset weaker flu vaccine sales, which were hit by "significantly" low ...

CSL consistency isn’t winning over investors, Ryan Stokes explains the new dump truck dance, and Macquarie’s return on equity ...

Australia Post is launching its first in-store retail media network, in partnership with oOh!media’s retail marketing arm, ...

Australia’s S&P/ASX 200 looks set to rise at the open, following a bounce in U.S. equities.

Tahmoor workers’ livelihoods are tied up with the fortunes of GFG Alliance, a company that is wracked with crisis on an international scale.

Shane Oliver has warned Aussies may be waiting until 2032 before real wages return to their 2020 peak, unless politicians cut ...

While the news on tariffs may be alarming, given how much of the nation's growth relies on exports, the US is a relatively small buyer of Australia’s steel and aluminium.

Sunshine Coast Council, one of Australia's largest, has backed a major restructure to cut costs but not before creating a new ...

With the end of the three-year federal government term rapidly approaching, Prime Minister Anthony Albanese could call an election any day now.

By Christine Chen (Reuters) -Australian biopharmaceutical company CSL said on Tuesday that falling immunisation rates in the U.S., its largest market, weighed on its vaccine sales and first-half ...